News | July 03, 2014

Mount Sinai Heart Establishes Pioneering Center for Medical Devices

Innovative Center will aid consultation, clinical trial design and testing of promising cardiac medical devices

July 3, 2014 — Mount Sinai Heart at Icahn School of Medicine at Mount Sinai has created an innovative Center for Medical Devices (CMeD) to advance the field of cardiovascular medicine and accelerate the delivery of promising medical devices to cardiac patients. Julie Swain, M.D., an experienced cardiothoracic surgeon and medical device expert has been recruited by Mount Sinai to help lead this pioneering initiative.

A practicing cardiothoracic surgeon for more than 25 years, Swain is also a clinical trials expert who has consulted for the U.S. Food and Drug Administration’s (FDA) Division of Cardiovascular Devices for 20 years. In addition to her role as director of CMeD, Swain will serve as professor of cardiovascular surgery and director of clinical research in the department of cardiovascular surgery at Mount Sinai.

“Our mission at CMeD will be to provide the critical expertise and guidance needed by medical device companies, inventors and researchers to further develop and test innovative cardiac medical devices that show promise to advance the field of cardiovascular medicine and the heart health of patients around the globe,” says Swain.

At Mount Sinai’s CMeD, Swain joins forces with Mount Sinai Heart’s internationally acclaimed leadership team including Valentin Fuster, M.D., Ph.D., director of Mount Sinai Heart and physician-in-chief at The Mount Sinai Hospital, and David H. Adams, M.D., chairman of the department of cardiovascular surgery, who are both members of CMeD’s executive leadership committee.

“Dr. Swain brings to Mount Sinai her vast expertise and knowledge in testing the latest medical device technology in clinical trials and navigating the regulatory approval process. Together, our CMeD team’s in-depth knowledge and experience in all aspects of designing and conducting clinical trials will improve the evaluation of promising cardiac medical devices at Mount Sinai Heart,” says Fuster.

“Dr. Swain is internationally acclaimed for her leadership as the key advisor on cardiac device trial design and data interpretation for the Food and Drug Administration over the past decade. She has been at the center of every major cardiac device trial in this role, and is thus uniquely positioned to lead our medical device program going forward. I expect this program to be a national level resource that will bring us access to a number of cutting edge clinical research opportunities, and assure our position as a leader in this space,” says Adams.

CMeD’s team will help further develop technologies and test medical devices in advanced clinical trials toward the strategic goal of regulatory approval, thus accelerating cardiac medical devices delivery to patients who may be in need of beneficial therapies. Services available through CMeD include cardiac medical device assessment and evaluation, regulatory approval strategies, advanced clinical trial design, data interpretation, assistance with FDA submissions and potential access to clinical testing at Mount Sinai.

In addition, CMeD will be a training center for future medical professionals wishing to gain experience in advanced clinical trial design and evaluation of medical devices.

“If you need help at any stage of your promising cardiac medical device’s research and development, ranging from the earliest development of your medical device to the final regulatory FDA approval, our experienced team at CMeD at Mount Sinai Heart can help,” says Swain.

For more information: www.mountsinai.org

Related Content

FDA Releases New Guidance on Medical Devices Containing Nitinol
News | Cath Lab | April 18, 2019
April 18, 2019 — The U.S.
Angiography shows a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL lithoplasty.

Figure 2: Angiography demonstrates a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification (double-headed arrow) in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL (inset; note the cavitation bubbles generated by IVL [black arrows]). (D) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-IVL and coregistered to the OCT lens (white arrow in C) demonstrate multiple calcium fractures and large acute luminal gain. (E) Angiography demonstrates complete stent expansion with the semicompliant stent balloon (inset) without the need for high-pressure noncompliant balloon inflation. (F) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-stenting and coregistered to the OCT lens (arrow in E) demonstrate further fracture displacement (arrow), with additional increase in the acute area gain (5.17 mm2), resulting in full stent expansion and minimal malapposition.

Feature | Cath Lab | April 15, 2019 | Dean Kereiakes, M.D., FACC, FSCAI, and Jonathan Hill, M.D., DISRUPT CAD III Co-Principal Investigators
Over the last 40 years, despite multiple advancements in percutaneous coronary interventions, calcified lesions remai
BIOTRONIK’s PK Papyrus covered coronary stent. The stent ius used in emergency coronary artery dissections to repair the vessel wall.
Technology | Cath Lab | April 15, 2019
April 15, 2019 — Biotronik began its U.S.
Providing Follow-Up Care After Heart Attack Helps Reduce Readmissions, Deaths
News | Cath Lab | April 09, 2019
A program designed to help heart attack patients with the transition from hospital to outpatient care can reduce...
TherOx Receives FDA Approval for SuperSaturated Oxygen Therapy
Technology | Cath Lab | April 08, 2019
TherOx Inc. announced that the U.S. Food and Drug Administration (FDA) granted premarket approval for its...
Cook Medical Recalls Transseptal Needle Due to Risk of Detached Plastic Fragments
News | Cath Lab | March 20, 2019
March 20, 2019 — Cook Medical is recalling one lot of its...
DABRA Excimer Laser System Demonstrates Success in Treating PAD
News | Cath Lab | February 27, 2019
Ra Medical Systems Inc. announced a 98 percent success rate in the results from a 52-patient study using the company’s...
Edwards Lifesciences Recalls Swan-Ganz hemodynamic catheters.
Feature | Cath Lab | February 06, 2019
Edwards Lifesciences is recalling its 131F7, 131F7J, 131F7P, 131VF7P, 151F7 Swan-Ganz Thermodilution Catheters manufa
Scientists Discover New Heart Attack Repair Pathway

A macrophage immune cell, with a dead cell (pink) that has been eaten, and a mitochondrion (green) between the dead cell and the nucleus. The study’s findings indicate that what the macrophage eats is taken up by the mitochondrion, which in turn communicates with the nucleus to activate the macrophage to promote tissue repair. Image courtesy of Northwestern Medicine.

News | Cath Lab | January 30, 2019
Northwestern Medicine scientists have discovered a novel signaling pathway that promotes healing after a heart attack....
Shockwave Initiates U.S. Pivotal Study for Coronary Intravascular Lithotripsy
News | Cath Lab | January 16, 2019
Shockwave Medical Inc. has initiated its U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE...
Overlay Init